Celyad Oncology SA (EBR:CYAD)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.3190
-0.0170 (-5.06%)
Aug 29, 2025, 5:35 PM CET
-5.06%
Market Cap15.04M
Revenue (ttm)186.00K
Net Income (ttm)-5.82M
Shares Out44.76M
EPS (ttm)-0.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume32,357
Average Volume37,067
Open0.3240
Previous Close0.3360
Day's Range0.3010 - 0.3240
52-Week Range0.2205 - 1.2200
Beta1.05
RSI35.84
Earnings DateSep 25, 2025

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 19
Stock Exchange Euronext Brussels
Ticker Symbol CYAD
Full Company Profile

Financial Performance

In 2024, Celyad Oncology's revenue was 186,000, an increase of 82.35% compared to the previous year's 102,000. Losses were -5.82 million, -31.06% less than in 2023.

Financial Statements

News

There is no news available yet.